Whitepaper: Accelerating pre-clinical and clinical trial pathways with target dose technology

The Lonza Xcelodose® powder microdosing system helps developers quickly assess new drug candidates while minimizing API consumption

Answering the needs of drug developers, the Lonza Engine® equipment portfolio including the Xcelodose® technology, a powder microdosing system, helps developers quickly assess new drug candidates while minimizing API consumption.

Download the whitepaper to learn how Lonza helps developers quickly assess new drug candidates while minimizing API consumption through efficient excipient screenings, encapsulation and early-phase clinical development technologies.

Download

To View, Please Provide the Following

Access all of the latest news, white papers, webinars and knowledge center resources.